FDA Labeling on Nayzilam Dosing Limits
Nayzilam (midazolam nasal spray) is approved for acute treatment of seizure clusters in patients 12 years and older. The prescribing information limits use to no more than one dose (two sprays total, one per nostril) per seizure cluster, with a maximum of one seizure cluster treated every 3 days. This equates to a recommended maximum of about twice per week.[1][2]
Why the Twice-a-Week Limit Exists
Frequent use risks tolerance, where higher doses may be needed for effect, and dependence on benzodiazepines like midazolam. Nasal administration can also lead to cumulative sedation, respiratory depression, or mucosal irritation. Clinical trials supporting approval (e.g., ARTEMIS1 and ARTEMIS2) showed safety at this frequency, but data beyond twice weekly is limited.[1][3]
What Happens with More Frequent Use
Using Nayzilam more than twice a week increases risks of serious side effects, including profound sedation, respiratory failure, coma, or withdrawal symptoms upon stopping. The label warns against daily or near-daily use, as it mirrors patterns seen with other benzodiazepines leading to addiction. Overuse has prompted FDA boxed warnings for all benzodiazepines.[1][4]
Patient Experiences and Real-World Reports
Some epilepsy patients report using rescue sprays like Nayzilam 3-5 times weekly under doctor supervision, but forums (e.g., epilepsy communities) highlight tolerance buildup within weeks and rebound seizures. No long-term studies endorse this; doctors often switch to alternatives if clusters exceed guidelines.[5]
Doctor Recommendations and Monitoring
Neurologists advise against exceeding the label without close monitoring, including EEGs and blood tests for tolerance. If clusters happen more than twice weekly, they recommend optimizing daily anti-seizure meds (e.g., adding clobazam) or non-drug options like the vagus nerve stimulator. Always consult a provider before adjusting.[1][6]
Alternatives for Frequent Seizure Clusters